Swiss drugmaker Roche said on Tuesday it had concluded price negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for its breast cancer therapy Perjeta (Pertuzumab).
The agreement aims to expand access to the drug, which is used alongside Trastuzumab and chemotherapy, for patients in Canada. The deal follows a positive recommendation from the Canadian drug agency (CDA-AMC) in October 2025 and advocacy from patient groups for broader reimbursement coverage.
Roche Canada said it would work with provincial and territorial authorities to clarify reimbursement terms promptly, enabling eligible patients to access the therapy as soon as possible. The company emphasized the urgency of making the treatment available given the aggressive nature of the disease it targets.
Perjeta is indicated for HER2-positive breast cancer, which accounts for 10% to 20% of all breast cancer cases in Canada. This subtype is associated with rapid disease progression and high relapse risk, making early-stage intervention critical to reducing recurrence rates.
The pCPA, which negotiates drug pricing on behalf of Canada’s provinces and territories, did not disclose financial terms of the agreement. The deal is part of broader efforts to align Canadian reimbursement policies with clinical need and patient advocacy.
